Cargando…

Long-term prognostic factors of chronic central serous chorioretinopathy after half-dose photodynamic therapy: A 3-year follow-up study

PURPOSE: To evaluate the long-term efficacy and factors involved in the recurrence and persistence of subretinal fluid (SRF) after half-dose photodynamic therapy (PDT) for chronic central serous chorioretinopathy (CSC). METHODS: In this retrospective observational case series, 79 eyes (73 patients)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Haga, Fuminori, Maruko, Ruka, Sato, Chiaki, Kataoka, Keiko, Ito, Yasuki, Terasaki, Hiroko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5524407/ https://www.ncbi.nlm.nih.gov/pubmed/28742138 http://dx.doi.org/10.1371/journal.pone.0181479

Ejemplares similares

Choroidal hemodynamics in central serous chorioretinopathy after half-dose photodynamic therapy and the effects of smoking
por: Horiguchi, Etsuyo, et al.
Publicado: (2022)

Half-dose Photodynamic Therapy for Chronic Central Serous Chorioretinopathy
por: Naseripour, Masood, et al.
Publicado: (2016)

No-Dose Photodynamic Therapy Against Half-Dose Photodynamic Therapy for Treatment of Central Serous Chorioretinopathy
por: Servillo, Andrea, et al.
Publicado: (2023)

Photoreceptor disruption in central serous chorioretinopathy treated by half-dose photodynamic therapy
por: Ratanasukon, Mansing, et al.
Publicado: (2013)

Microperimetric evaluation of chronic central serous chorioretinopathy after half-dose photodynamic therapy
por: Fujita, Kyoko, et al.
Publicado: (2012)

Macular sensitivity after half-dose verteporfin photodynamic therapy in central serous chorioretinopathy
por: Sanguansak, Thuss, et al.
Publicado: (2015)

Choroidal Structure after Half-Dose Photodynamic Therapy in Chronic Central Serous Chorioretinopathy
por: Alovisi, Camilla, et al.
Publicado: (2020)

Changes in macular sensitivity after half-dose photodynamic therapy for chronic central serous chorioretinopathy
por: Atik, Alp, et al.
Publicado: (2017)

Outcome of half-dose photodynamic therapy in chronic central serous chorioretinopathy with fovea-involving atrophy
por: van Rijssen, Thomas J., et al.
Publicado: (2020)

Half-dose verteporfin photodynamic therapy for bullous variant of central serous chorioretinopathy: a case report
por: Ng, Winnie WK, et al.
Publicado: (2011)

Changes in Choroidal Structures in Eyes with Chronic Central Serous Chorioretinopathy after Half-Dose Photodynamic Therapy
por: Kinoshita, Takamasa, et al.
Publicado: (2016)

Short-Term Choriocapillaris Changes in Patients with Central Serous Chorioretinopathy after Half-Dose Photodynamic Therapy
por: Nassisi, Marco, et al.
Publicado: (2017)

Subthreshold micropulse laser photocoagulation versus half-dose photodynamic therapy for acute central serous chorioretinopathy
por: Zeng, Miao, et al.
Publicado: (2022)

INCREASING EVIDENCE FOR THE SAFETY OF FOVEA-INVOLVING HALF-DOSE PHOTODYNAMIC THERAPY FOR CHRONIC CENTRAL SEROUS CHORIORETINOPATHY
por: Feenstra, Helena M. A., et al.
Publicado: (2023)

Diagnosis of central serous chorioretinopathy by deep learning analysis of en face images of choroidal vasculature: A pilot study
por: Aoyama, Yukihiro, et al.
Publicado: (2021)

Photodynamic Therapy and Central Serous Chorioretinopathy
por: Siaudvytyte, Lina, et al.
Publicado: (2012)

Comparison of efficacy between low-fluence and half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy
por: Alkin, Zeynep, et al.
Publicado: (2014)

Choroidal neovascularization secondary to half-dose photodynamic therapy for chronic central serous chorioretinopathy: A case report
por: Zhang, Zhengwei, et al.
Publicado: (2021)

One-year results of half-dose versus one-third-dose photodynamic therapy in chronic or recurrent central serous chorioretinopathy
por: Pichai, Jirarattanasopa, et al.
Publicado: (2021)

Half-fluence photodynamic therapy to treat chronic central serous chorioretinopathy: A case series
por: Al-Hinai, Ahmed S., et al.
Publicado: (2011)

Choroidal vascularity changes in idiopathic central serous chorioretinopathy after half-fluence photodynamic therapy
por: Ma, Dae Joong, et al.
Publicado: (2018)

3-year follow-up of half-dose verteporfin photodynamic therapy for central serous chorioretinopathy with OCT-angiography detected choroidal neovascularization
por: Hu, Yu-Chen, et al.
Publicado: (2021)

Choroidal atrophy in a patient with paraneoplastic retinopathy and anti-TRPM1 antibody
por: Ueno, Shinji, et al.
Publicado: (2014)

Long-Term Effect of Half-Fluence Photodynamic Therapy on Fundus Autofluorescence in Acute Central Serous Chorioretinopathy
por: Stattin, Martin, et al.
Publicado: (2020)

Half-fluence Photodynamic Therapy for Central Serous Chorioretinopathy in a Patient Receiving Corticosteroids for Behçet’s Uveitis
por: Özdemir, Hüseyin Baran, et al.
Publicado: (2022)

Improvement of Low Luminance Visual Acuity in Patients with Chronic Central Serous Chorioretinopathy after Half-Dose Verteporfin Photodynamic Therapy
por: Fujita, Kyoko, et al.
Publicado: (2020)

Decrease in choroidal blood flow after half and one-third dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy
por: Kumashiro, Shun, et al.
Publicado: (2021)

Comparison between 1-year outcomes of aflibercept with and without photodynamic therapy for polypoidal choroidal vasculopathy: Retrospective observation study
por: Takayama, Kei, et al.
Publicado: (2017)

Long-Term Effects of Half-Time Photodynamic Therapy on Retinal Sensitivity in Eyes with Chronic Central Serous Chorioretinopathy
por: Iwase, Takehito, et al.
Publicado: (2020)

Two-year outcome of half-time photodynamic therapy for chronic central serous chorioretinopathy with and without choroidal neovascularization
por: Kamimura, Aya, et al.
Publicado: (2023)

Subthreshold 577 nm micropulse laser treatment for central serous chorioretinopathy
por: Maruko, Ichiro, et al.
Publicado: (2017)

The relationship between foveal outer nuclear layer thickness in the active and resolved phases of central serous chorioretinopathy treated with half-dose photodynamic therapy
por: Yu, Jia, et al.
Publicado: (2019)

Changes of outer retinal microstructures after photodynamic therapy for chronic central serous chorioretinopathy
por: Shimizu, Kimiko, et al.
Publicado: (2017)

Effect of photodynamic therapy on choroid of the medial area from optic disc in patients with central serous chorioretinopathy
por: Funatsu, Ryoh, et al.
Publicado: (2023)

Real world outcomes of photodynamic therapy for chronic central serous chorioretinopathy
por: Khandhadia, Samir, et al.
Publicado: (2022)

Assessment of choriocapillary blood flow changes in response to half-dose photodynamic therapy in chronic central serous chorioretinopathy using optical coherence tomography angiography
por: Liu, Juejun, et al.
Publicado: (2020)

Prospective evaluation of changes in choroidal vascularity index after half-dose photodynamic therapy versus micropulse laser treatment in chronic central serous chorioretinopathy
por: van Rijssen, Thomas J., et al.
Publicado: (2020)

Effect of half adult dose of oral Rifampicin (300mg) in patients with idiopathic central serous chorioretinopathy
por: Khan, Muhammad Saim, et al.
Publicado: (2016)

Choroidal neovascularization emerged right from the focal choroidal excavation in eyes with central serous chorioretinopathy post half-dose photodynamic therapy: a case report
por: Liu, Yang, et al.
Publicado: (2019)

Quantitative evaluation of choriocapillaris using optical coherence tomography and optical coherence tomography angiography in patients with central serous chorioretinopathy after half-dose photodynamic therapy
por: Yang, Hyun Seung, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3rp9u1gj2feguoke7ag6cifar9